PD-L1 EXPRESSION AND HISTOLOGICAL TYPE AS PREDICTORS OF RESPONSE IN METASTASIC NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH PEMBROLIZUMAB IN FIRST LINE